Pembrolizumab, one such CPI recommended by guidelines (2, 4) is a programmed cell death (PD-1) inhibitor approved in the United States and Europe for the treatment of patients with unresectable or metastatic melanoma (5, 6). This evidence concerns the gene PDCD1 and metastatic melanoma.